RESUMEN
INTRODUCTION: The correction of a deep overbite with the subsequent achievement of long-term stability is a difficult problem for orthodontists. The role of leveling the curve of Spee (COS) in bite opening and the success of orthodontic treatment has been well documented in the literature. The aim of this study was to investigate whether leveling the COS, by using 2 orthodontic treatment techniques, produces stable results on a long-term basis. METHODS: We compared the long-term stability of leveling the COS with the straight-wire Alexander technique and the bioprogressive sectional-arch technique. The randomly selected subjects for this retrospective study were obtained from the private practices of Drs R. G. Alexander and Ruel Bench. Study models taken 2 months before treatment (T1), 2 months after treatment (T2), and after retention (T3) were evaluated. Measurements of the COS were made on the mandibular casts with a commercially available palatometer. Mandibular intercanine width, overbite, overjet, mandibular incisor irregularity, and mandibular arch length were also recorded. RESULTS AND CONCLUSIONS: Both techniques produced highly significant reductions in the COS (T1 to T2). Statistically significant, but clinically insignificant, postretention relapse of the COS occurred (T2 to T3). For both techniques, a statistically significant difference was seen in the incidence of the relapse of the COS between patients who were completely leveled posttreatment and those who were not. We did not find a correlation between pretreatment COS and relapse in any of the other occlusal traits studied.
Asunto(s)
Arco Dental/patología , Maloclusión Clase II de Angle/terapia , Alambres para Ortodoncia , Ortodoncia Correctiva/métodos , Cefalometría , Niño , Humanos , Estudios Longitudinales , Modelos Dentales , Ortodoncia Correctiva/instrumentación , Recurrencia , Estudios Retrospectivos , Resultado del Tratamiento , Dimensión VerticalAsunto(s)
Fructosa/análogos & derivados , Obesidad/tratamiento farmacológico , Adulto , Depresores del Apetito/uso terapéutico , Bupropión/uso terapéutico , Ciclobutanos/uso terapéutico , Dietilpropión/uso terapéutico , Fluoxetina/uso terapéutico , Fructosa/uso terapéutico , Derivación Gástrica , Gastroplastia , Humanos , Lactonas/uso terapéutico , Lipasa/antagonistas & inhibidores , Obesidad/cirugía , Orlistat , Fentermina/uso terapéutico , TopiramatoRESUMEN
BACKGROUND: The overexpression of transforming growth factor-beta (TGF-beta) in hepatocellular carcinoma (HCC) appears to induce immunosuppression toward the tumor cells. METHODS: A rat HCC cell line, Morris hepatoma rat cell line (MRH)-7777 (MRH), was transfected with antisense TGF-beta2 in pCEP-4 vector and used as immunotherapy against the development of wild-type tumors. An enzyme-linked immunosorbent assay (ELISA) confirmed that TGF-beta2 production was markedly lower for antisense modified cells as compared to wild-type tumor cells. Tumors were initiated by injecting MRH cells into the flanks of Buffalo rats. This was followed by biweekly vaccinations with irradiated MRH cells (unmodified, pCEP-4 alone, or antisense TGF-beta2 modified). RESULTS: In the group that received irradiated MRH unmodified cells, 55% of rats died from tumor burden, and 36% developed tumor regression. In the group that received irradiated MRH cells modified with pCEP-4 vector alone, 50% died from tumors and 33% had spontaneous regression. In animals treated with pCEP-4/TGF-beta antisense modified cells, none developed tumors. Cell-mediated cytotoxicity assays demonstrated a twofold increase in lytic activity in the effector cells of the animals treated with antisense modified cells. CONCLUSIONS: These results demonstrate the successful treatment of HCC tumors in rats by a HCC vaccine genetically altered with antisense TGF-beta2. Decreased production of TGF-beta in HCC vaccine enhances immunogenicity against wild-type HCC tumor cells.
Asunto(s)
Carcinoma Hepatocelular/terapia , ADN sin Sentido/uso terapéutico , Inmunoterapia/métodos , Neoplasias Hepáticas Experimentales/terapia , Factor de Crecimiento Transformador beta/biosíntesis , Factor de Crecimiento Transformador beta/genética , Animales , Carcinoma Hepatocelular/patología , Citotoxicidad Inmunológica , ADN sin Sentido/administración & dosificación , Modelos Animales de Enfermedad , Ensayo de Inmunoadsorción Enzimática , Expresión Génica/efectos de los fármacos , Vectores Genéticos , Humanos , Inyecciones Subcutáneas , Neoplasias Hepáticas Experimentales/patología , Trasplante de Neoplasias , Neoplasias/inducido químicamente , Plásmidos , Ratas , Ratas Endogámicas BUF , Retroviridae , Factor de Crecimiento Transformador beta2 , Células Tumorales Cultivadas , VacunaciónRESUMEN
Acute diverticulitis requiring surgical intervention has conventionally been treated by resection with colostomy or delayed resection with primary anastomosis at a second admission. Our objective was to determine the outcome for treatment of diverticulitis with resection and primary anastomosis during the same hospitalization. We conducted a retrospective review of patients (n = 74) undergoing surgery for diverticulitis. Groups included: 1) resection with primary anastomosis (n = 33), 2) resection with colostomy followed by a takedown colostomy (n = 32), and 3) delayed resection with primary anastomosis at a second admission (n = 9). Despite local perforation primary anastomosis was often performed unless patients were clinically unstable or had fecal contamination. The operation was urgent in five (15%) patients in Group 1 as compared with 26 patients (88%) in Group 2. Serious intra-abdominal complications occurred in two patients (6%) in Group 1 as compared with nine patients (28%) in Group 2 and one patient (11%) in Group 3. Postoperative abscesses occurred in two patients in Group 1, five patients in Group 2, and one patient in Group 3. We have shown that resection with primary anastomosis for acute diverticulitis--even in selected patients requiring urgent operation--can be safely performed during the same hospital admission with a low complication rate.
Asunto(s)
Colectomía , Diverticulitis del Colon/cirugía , Absceso Abdominal/etiología , Enfermedad Aguda , Adulto , Anastomosis Quirúrgica , Diverticulitis del Colon/diagnóstico por imagen , Femenino , Humanos , Masculino , Persona de Mediana Edad , Complicaciones Posoperatorias , Estudios Retrospectivos , Tomografía Computarizada por Rayos XRESUMEN
BACKGROUND: Optimization of oxygen delivery remains the best method to prevent and the only way to treat common intensive care unit syndromes such as sepsis, multiple organ dysfunction, and acute lung injury. This paper reviews the elements of oxygen delivery, describes how clinical interventions work through those elements to alter oxygen delivery, reviews theoretical and empirical data relating to manipulation of each element, and distinguishes between therapeutic means and clinical endpoints in the care of the critically ill. MATERIALS AND METHODS: Recent literature is reviewed. Relevant equations are detailed. Computer models and patient data illustrate key points. RESULTS: Clinical interventions intended to improve oxygen delivery all work through at least one of seven variables (oxygen saturation, hemoglobin concentration, heart rate, mean arterial blood pressure, systemic vascular resistance, end-diastolic volume, and ejection fraction). Because interventions that increase oxygen delivery are always accompanied by physiologic costs, cavalier application of any therapy in the intensive care unit may actually decrease oxygen delivery, harming the critically ill patient. Various clinical indicators may be used as endpoints to guide therapy. CONCLUSIONS: While a systematic consideration of the elements of oxygen delivery reveals weaknesses in experimental evidence guiding optimal treatment of shock, reasonable strategies as well as avoidable pitfalls emerge from the data. Furthermore, facility with each of the elements of oxygen delivery makes ICU management easier to teach and to apply.
Asunto(s)
Enfermedad Aguda/terapia , Cuidados Críticos/métodos , Terapia por Inhalación de Oxígeno/métodos , HumanosRESUMEN
Congenital anatomic anomalies often present technical obstacles during liver transplants. Biliary atresia is the most common indication for liver transplants in children, and approximately 7-10% of these patients have congenital anomalies comprising the "polysplenia syndrome." The polysplenia syndrome, which often includes abdominal situs inversus, is of particular concern in liver transplants because these anatomic anomalies result in a more complex hepatectomy, alterations in the placement of the donor grafts, and the need for additional vascular reconstruction. Earlier reports have shown mixed results for these patients who have undergone orthotopic liver transplants, reporting a high rate of postoperative complications and poor survival. The use of living-related donor grafts has produced excellent results in the general pediatric population. This is the first report of the successful use of a living-related donor graft for an orthotopic liver transplant to treat end-stage liver disease secondary to biliary atresia in a child with polysplenia syndrome.
Asunto(s)
Trasplante de Hígado , Bazo/anomalías , Bazo/cirugía , Atresia Biliar/complicaciones , Atresia Biliar/etiología , Atresia Biliar/cirugía , Femenino , Humanos , Lactante , Donadores Vivos , Ilustración Médica , Bazo/patologíaRESUMEN
Current standard of care for complicated diverticulitis includes urgent resection with colostomy versus antibiotic treatment, followed by delayed resection with primary anastomosis at a second admission. In certain circumstances, it is possible to perform resection and anastomosis on the same admission for acute diverticulitis. A retrospective review was completed for patients undergoing surgery for diverticulitis from 1991 to 1998. Groups included: 1) sigmoid resection with primary anastomosis on same admission (n = 18); 2) resection with protective end colostomy (n = 16); and 3) in-patient antibiotic treatment alone, followed by a second admission for resection with primary anastomosis (n = 5). Four patients initially treated with antibiotics worsened symptomatically or developed radiographic evidence of perforation and required resection with colostomy. Five patients in Group 1 had abscesses or contained perforations based on radiographic studies. Findings on CT scans did not predict treatment. Group 1 patients had uneventful recoveries and few minor complications (wound infections and an incisional hernia). One anastomotic leak occurred in Group 2 after colostomy closure. Although there will continue to be a role for emergent operation for diverticulitis, same admission sigmoid resection with primary anastomosis after antibiotic treatment is safe, uses a shorter course of antibiotics, and has a low complication rate.
Asunto(s)
Colon Sigmoide/cirugía , Diverticulitis del Colon/cirugía , Hospitalización , Enfermedad Aguda , Adulto , Anastomosis Quirúrgica , Procedimientos Quirúrgicos del Sistema Digestivo/métodos , Humanos , Persona de Mediana Edad , Complicaciones Posoperatorias , Estudios RetrospectivosRESUMEN
BACKGROUND AND OBJECTIVES: Fas (APO-1) induces apoptosis after binding Fas ligand (FasL). Evidence suggests that tumors may use this interaction to evade the host immune response. Fas/FasL expression has not been reported in esophageal cancer. We hypothesized that Fas expression would render esophageal cancer cells susceptible to Fas ligation and that irradiation of the cells would increase Fas expression. METHODS: Two human esophageal squamous cell carcinoma lines, KYSE 150, which has a wild-type (wt) p53 gene, and 410 (mutated p53), were irradiated. Reverse-transcriptase polymerase chain reaction was used to detect Fas and FasL expression. Fas protein was quantitated by enzyme-linked immunosorbent assay and its presence further confirmed by Western analysis. FasL was detected by Western analysis. Cells were treated with Fas monoclonal antibody (maximum 0.05 microg/ml)+/-cycloheximide, and viability was assessed by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. Cells were also transduced with FasL cDNA and then quantified. RESULTS: Both lines expressed Fas and FasL, but only the KYSE 150 cell line displayed an increase in Fas following irradiation. No alteration in cell growth was detected for Fas antibody- or FasL-transduced groups versus controls. CONCLUSIONS: We have demonstrated Fas and FasL expression in esophageal tumor lines. We have also shown that Fas levels are significantly increased in response to irradiation in a wt p53 line. However, cells were resistant to treatment with Fas antibody or following transduction with FasL, suggesting that these tumor cells may use Fas/FasL expression to evade the host immune response.
Asunto(s)
Apoptosis , Carcinoma de Células Escamosas/inmunología , Neoplasias Esofágicas/inmunología , Regulación hacia Arriba/efectos de la radiación , Receptor fas/fisiología , Carcinoma de Células Escamosas/genética , Carcinoma de Células Escamosas/patología , Neoplasias Esofágicas/genética , Neoplasias Esofágicas/patología , Proteína Ligando Fas , Genes p53 , Humanos , Ligandos , Glicoproteínas de Membrana/metabolismo , Transducción de Señal , Células Tumorales Cultivadas , Receptor fas/metabolismoAsunto(s)
Enfermedad Coronaria/prevención & control , Ciclosporina/uso terapéutico , Trasplante de Corazón/inmunología , Trasplante de Corazón/patología , Isoanticuerpos/sangre , Animales , Formación de Anticuerpos , Enfermedad Coronaria/etiología , Enfermedad Coronaria/inmunología , Inmunoglobulina G/sangre , Inmunoglobulina M/sangre , Inmunosupresores/uso terapéutico , Isoanticuerpos/biosíntesis , Complicaciones Posoperatorias , Ratas , Ratas Endogámicas F344 , Ratas Endogámicas Lew , Trasplante Homólogo/inmunologíaRESUMEN
OBJECTIVE: To analyze a single center's 13-year experience with 569 pediatric orthotopic liver transplants for end-stage liver disease. SUMMARY BACKGROUND DATA: Despite advances in medical therapy, liver replacement continues to be the only definitive mode of therapy for children with end-stage liver disease. Innovative surgical techniques and improved immunosuppression have broadened the application of liver replacement for affected children. However, liver transplantation in the child remains challenging because of the scarcity of donor organs, complex surgical technical demands, and the necessity to prevent long-term complications. METHODS: The medical records of 440 consecutive patients younger than 18 years of age undergoing orthotopic liver transplantation for end-stage liver disease from March 20, 1984, to November 15, 1997, were reviewed. Results were analyzed using Cox multivariate regression analysis to determine the statistical strength of independent associations between pretransplant covariates and patient and graft survival. Actuarial patient and graft survival rates were determined at 1, 3, 5, and 10 years. The type and incidence of posttransplant complications were determined, as was the quality of long-term allograft function. The median follow-up period was 4.1 years. RESULTS: Biliary atresia was the most common cause (50.4%) of endstage liver disease in this patient population. The median recipient age was 2.4 years; 239 patients (54%) were younger than 3 years of age and 1 11 patients (25%) were younger than 1 year of age. There were 471 whole organs, 29 were ex vivo reduced size, 33 were living-related donor, and 36 were in situ split-liver allografts. Three hundred forty-three (78%) patients underwent a single allograft, whereas 97 patients required retransplantation; hepatic artery thrombosis was the most common indication for retransplantation (55 patients). The 1-, 3-, 5-, and 10-year actuarial patient survival rates were 82%, 80%, 78%, and 76%, respectively; allograft survival rates were 68%, 63%, 60%, and 54%. Long-term liver function remains excellent: current median follow-up values for total bilirubin and aspartate aminotransferase were 0.5 mg/dl and 54 IU/L, respectively. Cox multivariate regression analysis demonstrated that pretransplant patient age, the era of transplantation, and the number of allografts performed significantly and independently predicted patient survival rates, whereas allograft type and pretransplant diagnosis did not. CONCLUSIONS: Liver transplantation in the pediatric patient is a durable procedure that provides excellent long-term survival. Although there have been overall improvements in patient outcome with increased experience, the effect is most pronounced for patients younger than 1 year of age. Retransplantation, although effective in a meaningful number of patients, continues to carry a progressive decrement in survival with the number of allografts performed. Use of living-related and in situ split-liver allografts has dramatically reduced waiting times for small children and has improved patient survival.
Asunto(s)
Fallo Hepático/cirugía , Trasplante de Hígado , Análisis Actuarial , Adolescente , Niño , Preescolar , Estudios de Seguimiento , Supervivencia de Injerto , Humanos , Terapia de Inmunosupresión , Lactante , Fallo Hepático/mortalidad , Trasplante de Hígado/efectos adversos , Análisis Multivariante , Complicaciones Posoperatorias/epidemiología , Tasa de Supervivencia , Factores de TiempoRESUMEN
Polycystic liver disease, commonly associated with polycystic kidney disease, can result in massive hepatomegaly and debilitating symptoms. Surgical intervention for symptomatic polycystic liver disease has been associated with significant morbidity and inconsistent long-term palliation; it is more appropriate in patients with a single dominant cyst or cysts which is/are confined to one lobe. At our institution, nine patients have undergone orthotopic liver transplantation for symptomatic hepatic cysts with excellent long-term results and minimal morbidity and mortality. Surgical candidates were selected based on severe limitations in daily activities and on sequelae of hepatic cystic involvement. Other factors considered were the extent and pattern of hepatic cystic disease, the degree of hepatic and renal dysfunction, and prior surgical intervention. Three patients (33%) required combined liver and kidney transplantation because of renal cystic involvement with renal insufficiency. The one-year survival rate was 89% with excellent symptomatic relief and improved quality of life in all the surviving patients. One death occurred in a significantly malnourished 62-year-old female. Complications included one case each of hepatic artery thrombosis requiring retransplantation, biliary leak necessitating biliary reconstruction, and postoperative bleeding requiring re-exploration. The mean hospital stay was 23 days and the mean intraoperative blood transfusion requirement was 18 units. Our experience demonstrates that appropriately selected patients with extensive hepatic involvement with adult polycystic liver disease can have an excellent outcome with transplantation, with morbidity comparable with other surgical options.
Asunto(s)
Quistes/cirugía , Hepatopatías/cirugía , Trasplante de Hígado , Adulto , Quistes/diagnóstico por imagen , Femenino , Humanos , Hepatopatías/diagnóstico por imagen , Masculino , Persona de Mediana Edad , Complicaciones Posoperatorias/cirugía , Reoperación , Análisis de Supervivencia , Tomografía Computarizada por Rayos X , Resultado del TratamientoRESUMEN
OBJECTIVE: To review the clinical characteristics, outcomes, and risk factors for survival among 57 pediatric patients undergoing orthotopic liver transplantation for fulminant hepatic failure at the University of California, Los Angeles, Center for the Health Sciences. DESIGN: The medical records of 57 consecutive pediatric patients undergoing orthotopic liver transplantation for fulminant hepatic failure from July 1, 1984, to June 25, 1997, were reviewed and survival data were analyzed via univariate and multivariate statistical methods. The type and incidence of posttransplant complications were determined as was the quality of long-term graft function. Median follow-up period was 3.38 years (range, 0-10.02 years). RESULTS: The 1-, 3-, and 5-year actuarial patient survival rates were 77%, 77%, and 77%, respectively, while graft survivals were 73%, 65%, and 65%. Stepwise Cox regression analysis revealed that recipient age and ventilator dependency at the time of transplantation were independently and significantly correlated with patient survival, whereas no association was found between survival and grade of encephalopathy, prior abdominal surgery, recipient weight, pretransplantation values for total bilirubin or prothrombin time, ABO match, allograft type, peak posttransplantation aspartate aminotransferase levels, or the presence of posttransplantation hepatic artery thrombosis. Non-ventilator-dependent patients demonstrated a 96% 1-, 3-, and 5-year survival as compared with only 56% at these same time points for those children requiring ventilator support at the time of transplantation (P < .001). At the time of most recent follow-up, median values for total bilirubin and aspartate aminotransferase concentrations were 10.3 micromol/L (0.6 mg/dL) and 56 U/L, respectively, in the 40 surviving patients. CONCLUSIONS: In children undergoing liver transplantation for fulminant hepatic failure: (1) overall results are comparable to those achieved for less emergent non-neoplastic indications in this same age group; (2) ventilator dependency prior to transplantation is the strongest predictor of ultimate survival, followed by recipient age; (3) 5-year survival exceeds 90% in recipients who are ventilator independent immediately prior to liver transplantation but is significantly compromised once the need for mechanical ventilation supervenes, particularly in those younger than 4 years; and (4) prompt referral and timely liver replacement are the cornerstones of optimal outcome.
Asunto(s)
Encefalopatía Hepática/cirugía , Trasplante de Hígado , Análisis Actuarial , Adolescente , Niño , Preescolar , Femenino , Supervivencia de Injerto , Encefalopatía Hepática/mortalidad , Humanos , Lactante , Trasplante de Hígado/efectos adversos , Trasplante de Hígado/mortalidad , Masculino , Análisis de Supervivencia , Resultado del TratamientoAsunto(s)
Población Negra , Rechazo de Injerto/epidemiología , Trasplante de Hígado/inmunología , Población Blanca , Enfermedad Aguda , Adulto , Negro o Afroamericano/estadística & datos numéricos , California , Ciclosporina/uso terapéutico , Femenino , Rechazo de Injerto/patología , Supervivencia de Injerto , Humanos , Inmunosupresores/uso terapéutico , Incidencia , Trasplante de Hígado/mortalidad , Trasplante de Hígado/patología , Masculino , Persona de Mediana Edad , Estudios Retrospectivos , Factores de Riesgo , Tasa de Supervivencia , Tacrolimus/uso terapéutico , Población Blanca/estadística & datos numéricosRESUMEN
BACKGROUND: Pravastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, inhibits coronary transplant vasculopathy in the clinical setting. To further delineate the immune modulatory effect of this agent, it was tested in a rat cardiac transplant model of chronic rejection. METHODS: Rat heterotopic abdominal cardiac transplants were performed using a Lewis to Fischer 344 combination. Fischer 344 recipients received a brief course of cyclosporine to decrease the incidence of acute rejection. Experimental groups were treated with either high-dose (10 mg/kg) or low-dose (5 mg/kg) pravastatin for 120 days, while a control group did not receive pravastatin. The effect of pravastatin on chronic rejection of cardiac allografts was analyzed by histology, and the expression of laminin, fibronectin, macrophages, and T cells was assessed by immunohistochemistry. RESULTS: Coronary transplant vasculopathy was inhibited in both groups of pravastatin-treated animals, as compared with controls. Immunohistochemistry revealed that control animals had degraded laminin and fibronectin which paralleled the degree of tissue necrosis. In contrast, pravastatin-treated animals had modest amounts of extracellular matrix proteins retained within intermyocytes and endothelium, a pattern seen in native cardiac tissue. The pravastatin-treated groups also had fewer graft-infiltrating macrophages, specifically within the arterial intima and perivascular areas. CONCLUSIONS: Progressive chronic vascular rejection, a leading cause of allograft failure, can be inhibited by pravastatin in a well-defined rat cardiac transplant model. Pravastatin appears to inhibit the synthesis and subsequent degradation of extracellular matrix proteins and block the infiltration of macrophages to the graft, which emphasizes that this inflammatory cell plays a major role in the pathogenesis of transplant chronic rejection.
Asunto(s)
Rechazo de Injerto/prevención & control , Trasplante de Corazón/inmunología , Inhibidores de Hidroximetilglutaril-CoA Reductasas/farmacología , Pravastatina/farmacología , Animales , Proteínas de la Matriz Extracelular/metabolismo , Rechazo de Injerto/metabolismo , Rechazo de Injerto/patología , Trasplante de Corazón/patología , Inmunohistoquímica , Macrófagos , Masculino , Ratas , Ratas Endogámicas F344 , Ratas Endogámicas Lew , Trasplante HomólogoRESUMEN
BACKGROUND: Fas ligand (FasL) induces apoptosis of cells bearing its receptor Fas, and has been shown to be important in T-cell development and regulation and in immune privilege. We hypothesized that FasL expression by renal allografts might provide protection from rejection. METHODS: The murine FasL cDNA was cloned into a replication-defective adenovirus (AdV-FasL). Protein expression was confirmed by immunostaining of AdV-FasL-transduced HeLa cells. Allogeneic kidney transplants were performed between WF (RT1u) donors and Lewis (RT1) recipients. Donor kidneys were perfused in situ with saline alone (control), or 9 x 10(9) plaque-forming units of AdV-FasL. One native kidney was removed at the time of transplant and the other at 6 or 7 days. Uremic death was the endpoint, and deaths within 7 days of transplant were excluded. Transduced allografts were stained for FasL expression using a monoclonal antibody and tested for FasL mRNA production by reverse transcriptase-polymerase chain reaction and Northern blotting. RESULTS: Immunostaining of AdV-FasL-transduced allografts demonstrated efficient gene transfer lasting approximately 2 weeks, and FasL mRNA production in the AdV-FasL-transduced allografts was confirmed by Northern blotting and reverse transcriptase-polymerase chain reaction. Mean survival of animals with AdV-FasL-transduced renal allografts was 27.8 days vs. 11.6 days in control animals (P < 0.05). CONCLUSIONS: (1) Adenoviral vectors can successfully transduce rat kidneys with the FasL cDNA. (2) FasL gene transfer prolongs rat renal allograft survival.
Asunto(s)
Citotoxicidad Inmunológica , Rechazo de Injerto/metabolismo , Supervivencia de Injerto , Trasplante de Riñón/inmunología , Glicoproteínas de Membrana , Trasplante Homólogo/inmunología , Adenoviridae , Animales , Citotoxicidad Inmunológica/genética , ADN Complementario , Proteína Ligando Fas , Técnicas de Transferencia de Gen , Rechazo de Injerto/inmunología , Rechazo de Injerto/prevención & control , Supervivencia de Injerto/genética , Supervivencia de Injerto/inmunología , Células HeLa , Humanos , Inmunohistoquímica , Trasplante de Riñón/patología , Glicoproteínas de Membrana/genética , Glicoproteínas de Membrana/inmunología , Glicoproteínas de Membrana/metabolismo , Reacción en Cadena de la Polimerasa , ARN Mensajero/análisis , Ratas , Ratas Endogámicas Lew , Ratas Endogámicas WF , Transducción Genética , Trasplante Homólogo/patologíaRESUMEN
Pravastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, has been shown to decrease the number of acute rejection episodes in cardiac and renal transplant patients. This study evaluates the effects of pravastatin on survival of rats following liver transplant and attempts to elucidate the mechanisms of these effects. Both survival and natural killer cell enhancing factor (NKEF) studies utilized Dark Agouti rats for donor livers transplanted into Brown Norway rats as recipients. All rats received daily low-dose cyclosporine (CsA) 2 mg/kg/day by gavage. The treated groups also received gavage doses of pravastatin, 20 mg/kg/day. Survival data were analyzed by the method of Kaplan-Meier and log-rank chi 2 tests for statistical significance. For NKEF evaluation, rats were sacrificed at varying time points; total RNA was extracted from the liver and hybridized with 32P-radiolabeled NKEF DNA probes in the Northern blot technique. Radiographs were quantitated using densitometry. Data were analyzed by two-way ANOVA. Actuarial survival was improved (P < < 0.05) in rats treated with pravastatin in addition to low-dose CsA (n = 41, CsA alone n = 74). Less fibrosis and chronic rejection was seen on histological section in the treated animal livers, P < 0.05, NKEF was seen maximally at Days 5-15 tapering off at Day 21. NKEF-a and NKEF-b levels were significantly decreased in the animals treated with CsA and pravastatin compared to CsA alone in the group of animals < 16 days postop (P < < 0.05). Pravastatin improves survival in rats following OLT and while the mechanism is still unknown, inhibition of natural killer cell enhancement factor may represent an alteration in the overall immune response.
Asunto(s)
Proteínas Sanguíneas/biosíntesis , Supervivencia Celular/efectos de los fármacos , Inhibidores Enzimáticos/farmacología , Inhibidores de Hidroximetilglutaril-CoA Reductasas , Inmunosupresores/farmacología , Células Asesinas Naturales/inmunología , Pravastatina/farmacología , Animales , Proteínas Sanguíneas/genética , Ciclosporina/administración & dosificación , Rechazo de Injerto/patología , Proteínas de Choque Térmico , Hígado/patología , Trasplante de Hígado/inmunología , Trasplante de Hígado/patología , Peroxidasas , Peroxirredoxinas , Ratas , Ratas Endogámicas , Análisis de SupervivenciaRESUMEN
The carboxy-terminal domain of recombinant human Mullerian inhibiting substance (MIS) inhibits cellular proliferation in vitro and decreases epidermal growth factor (EGF)-dependent phosphorylation of the EGF receptor. Proteolytically cleaved and undissociated MIS is more potent than carboxy-terminal MIS alone, supporting a functional role for the amino-terminal region of the molecule. MIS does not block EGF binding to the EGF receptor, thus, MIS reduction of EGF receptor phosphorylation must occur distal to receptor ligand binding. The effect of proteolytically cleaved MIS on reduction of EGF receptor phosphorylation in membrane preparations is decreased by a specific phosphatase inhibitor, vanadate, thus implicating a membrane phosphatase in this MIS action at the EGF receptor.
Asunto(s)
Membrana Celular/enzimología , Receptores ErbB/efectos de los fármacos , Glicoproteínas , Inhibidores de Crecimiento/farmacología , Conductos Paramesonéfricos/fisiología , Proteínas Tirosina Fosfatasas/metabolismo , Hormonas Testiculares/farmacología , Hormona Antimülleriana , Recuento de Células , Ciclo Celular , Receptores ErbB/metabolismo , Fibrinolisina/metabolismo , Humanos , Fosforilación , Fosfotransferasas/metabolismo , Células Tumorales CultivadasRESUMEN
OBJECTIVE: To establish whether specific K-ras alterations are predictive of less aggressive tumor behavior and subsequently those patients who are most likely to benefit from resection of hepatic metastases from colorectal carcinoma. DESIGN: Evaluation of long-term survivors of hepatic resection for metastases of colorectal carcinoma (median survival, 85 months). RESULTS: DNA, extracted from 26 paraffin-embedded hepatic metastases from 19 patients, was analyzed using single-strand conformation polymorphism and direct sequence analysis of codons 12 and 13 of the K-ras gene. Seven of 19 patients were found to harbor K-ras mutations. A similar frequency and spectrum of K-ras mutational events was detected in 14 patients with short-term survival following pathologic diagnosis of hepatic metastasis. CONCLUSIONS: Neither the presence of a K-ras mutational event nor the precise nucleotide change are predictive of less aggressive tumor behavior, and genetic alterations at this locus alone cannot be used to select patients undergoing resection of hepatic metastases from colorectal carcinoma.